Sapmaz, ErsinÇaylak, HasanKavaklı, KuthanGamsızkan, MehmetŞirin, Yusuf SinanGenç, Onur2020-04-302020-04-3020181301-5680https://doi.org/10.5606/tgkdc.dergisi.2018.16078https://hdl.handle.net/20.500.12684/3483Sapmaz, Ersin/0000-0003-1252-2714;WOS: 000450917400012PubMed: 32082803Background: This study aims to investigate the preventive effect of proanthocyanidin against ischemia-reperfusion injury after lung transplantation. Methods: The study included 12 swines (weighing 35 +/- 5 kg) and separated into four groups. Groups 1 and 3 were identified as control groups and left upper lobectomy was performed. Groups 2 and 4 were identified as transplantation groups and left lower lobectomy and heterotransplantation were performed. Proanthocyanidin was only given to groups 3 and 4. Tissue samples were analyzed under light microscope and histopathological findings were recorded. Results: There was no statistically significant difference between control groups in terms of the numerical values of histopathological findings that include congestion (p=0.565), alveolar edema (p=0.197) and peribronchial inflammation (p=0.444). However, numerical values of acute cellular rejection were statistically significantly different between transplantation groups (p=0.048). Mean oxidative stress enzyme levels were higher in group 2 compared to group 4; however, the difference was not statistically significant (p>0.05). Conclusion: According to the findings of our experimental study, proanthocyanidin can be safely used in lung transplantation based on its preventive effect in ischemia-reperfusion injury that may lead to morbidity and mortality.en10.5606/tgkdc.dergisi.2018.16078info:eu-repo/semantics/openAccessExperimentalischemia-reperfusionlung transplantationoxidative stressproanthocyanidinArticle264606613WOS:000450917400012Q3Q4